Belimumab Versus Anifrolumab in Adults with Systemic Lupus Erythematosus: An Indirect Comparison of Clinical Response at 52 Weeks
Lupus Sci. Med 2023;10:e000907 doi 10.1136/lupus-2023-000907
Belimumab and anifrolumab are both approved treatments for SLE, but there have been no head-to-head randomised clinical trial comparisons between the two drugs. Previous studies have used indirect comparisons, but they did not meet fundamental requirements for robust population-adjusted analysis.
